NCT01596270

GPTKB entity

Statements (24)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:ageRange 18 years and older
gptkbp:clinicalTrialPhase Phase 3
gptkbp:clinicalTrialsGovURL https://clinicaltrials.gov/ct2/show/NCT01596270
gptkbp:collaboratesWith gptkb:Eli_Lilly_and_Company
gptkbp:completedIn April 2015
gptkbp:conditionStudied gptkb:Type_2_Diabetes_Mellitus
gptkbp:enrollment 7020
gptkbp:gender All
https://www.w3.org/2000/01/rdf-schema#label NCT01596270
gptkbp:intervention gptkb:Placebo
gptkb:Empagliflozin
gptkbp:location Multinational
gptkbp:officialName A Study of BI 10773 (Empagliflozin) in Patients With Type 2 Diabetes Mellitus at High Risk for Cardiovascular Events
gptkbp:otherName EMPA-REG OUTCOME
gptkbp:primaryCompletionDate April 2015
gptkbp:result Time to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
gptkbp:secondaryOutcome All-cause mortality
Hospitalization for heart failure
gptkbp:sponsor gptkb:Boehringer_Ingelheim
gptkbp:startDate April 2012
gptkbp:studyType Interventional
gptkbp:bfsParent gptkb:XL518
gptkbp:bfsLayer 8